Literature DB >> 28922454

Surgery for T4 lung cancer invading the thoracic aorta: Do we push the limits?

Giuseppe Marulli1, Erino A Rendina2,3,4, Walter Klepetko5, Reinhold Perkmann6, Davide Zampieri1, Giulio Maurizi2,3,4, Thomas Klikovits5, Francesco Zaraca6, Federico Venuta2,3,4, Egle Perissinotto1, Federico Rea1.   

Abstract

BACKGROUND: Few investigators have described en bloc resection of non-small cell lung cancer (NSCLC) invading the aorta.
AIM OF STUDY: Analysis of outcome and prognostic factors for en bloc resections of NSCLC invading the aorta.
METHODS: Thirty-five patients (27 males, 8 females; mean age 63 ± 8.6 years) were operated between 1994 and 2015 in four European Centers. HISTOLOGY: 12 (34.3%) squamous cell carcinoma, and 6 (17.1%) undifferentiated/large cell carcinoma. The site of aortic infiltration was the descending thoracic aorta in 24 (68.6%) patients, the aortic arch in 9 (25.7%), and the aortic arch and supraortic trunks in 2 (5.7%).
RESULTS: Lung resection consisted of pneumonectomy in 19 (54.3%) patients and lobectomy in 16 (45.7%). Aortic resection management was undertaken by endograft positioning (37.1%), subadventitial dissection (37.1%), cardiopulmonary/aorto-aortic bypass (17.2%), and direct clamping (8.6%). A tubular graft replacement was carried out in five cases, a synthetic patch repair in 6. Mortality was 2.9%, morbidity 37.1%. Patients undergoing pneumonectomy had a significantly higher morbidity rate compared with lobectomy (52% vs 18.7%; P = 0.003), although patients managed with aortic endografting had a lower complication rate. Median overall and disease-free survival rates were 31.3 and 22.2 months, respectively. Gender and site of aortic infiltration were independent prognostic factors.
CONCLUSIONS: Resection of NSCLC combined with an infiltrated aorta is a challenging procedure that can be performed with reasonable morbidity and mortality in highly selected patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  aorta; aortic operation; endovascular procedures; lung cancer; lung cancer surgery

Mesh:

Year:  2017        PMID: 28922454     DOI: 10.1002/jso.24784

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-What is the evidence?

Authors:  Ilkka Ilonen; David R Jones
Journal:  Shanghai Chest       Date:  2018-10-11

2.  Validation of stage groupings in the eighth edition of the tumor node metastasis classification for lung adenocarcinoma.

Authors:  Wenguan Yu; Qingchun Zhao; Chunqiu Xia; Ming Dong; Jinghao Liu; Xin Li; Honglin Zhao; Gang Chen; Hongyu Liu; Jun Chen
Journal:  Thorac Cancer       Date:  2019-01-16       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.